CannabisNewsWire
Editorial Coverage: The U.S. Farm Bill that recently passed
into law is a game-changer for the CBD space. While it is unknown
when nationwide cannabis legalization may occur, incredible
opportunities exist right now for CBD-focused companies that can
deliver products to the marketplace.
- Demand is growing for organic CBD products in markets where
such products are legal.
- Youngevity has made a series of strategic acquisitions to help
establish the company’s position
- Companies ready to deliver CBD products to market at scale are
in ideal position to capitalize on growing demand.
Passage of the latest U.S. Farm Bill marked a watershed moment
for CBD producers in the United States. Not only does the new body
of law allow these producers to commercialize existing CBD
products, the door is now open for a new generation of research
into what CBD can do for consumers. Youngevity
International Inc. (NASDAQ: YGYI) (YGYI
Profile) is a leading producer of consumer-focused CBD
products that is expanding its reach into other areas of the CBD
supply chain. It joins companies such as CV Sciences Inc.
(OTCQB: CVSI), Isodiol International Inc. (CSE:
ISOL) (OTCQB: ISOLF), GW Pharmaceuticals plc
(NASDAQ: GWPH) (OTC: GWPRF), and Curaleaf Holdings
Inc. (OTCQX: CURLF) (CSE: CURA), which are all working to
commercialize CBD products in both the consumer and pharmaceutical
sectors.
To view an infographic of this editorial, click here.
CBD Offers New Opportunities for Bold
Thinkers
The market for CBD products is
exploding and likely will continue to grow as these products
become more available. Because CBD can be made in a laboratory, an
increasing amount of synthetically produced CBD has been entering
the market. However, many CBD proponents contend that organic CBD
(CBD extracted from hemp plants) is superior to synthetic CBD.
Youngevity
International Inc. (NASDAQ: YGYI) produces a range of
consumer-focused CBD products, but the company is growing its reach
via strategic acquisitions. Sourcing organic CBD has been an issue
for many manufacturers, which may be why Youngevity recently
acquired Khrysos Global — a CBD producer based in Florida.
Following the announcement of this acquisition to the public,
YGYI president and CFO Dave Briskie commented,
“We set out a plan to create a vertical opportunity in the hemp
space. This is a significant step as it relates to the production,
cultivation, and extraction of hemp, CBD oil, as well as other CBs
(cannabinoids). . . . We proudly welcome Dwayne Dundore, as the
President of newly formed Khyrsos (sic) Industries along with his
entire and very capable team at Khrysos and INX Labs.”
Dundore was equally enthusiastic about the announcement, saying,
“I am really excited to be a YGYI shareholder and part of the
Youngevity Family. I look forward to making a meaningful
contribution to both the top and bottom line of the company and
feel strongly that our capabilities and plans for expansion should
create additional value for myself and all shareholders.”
CBD Ready to Take the Market by Storm
Unlike THC, which is a highly psychoactive alkaloid found in
cannabis, CBD has a calming effect in most people. In addition, CBD
can be legally sold without a prescription and is being integrated
into many consumer products.
CBD companies that can create good connections with their client
bases should be able to grow into this burgeoning market.
Recognizing this, Youngevity has made a series of strategic
acquisitions that could help establish the company’s position as a
leader in 21st-century cannabis development. The
company’s takeover of Khrysos Global netted it a solid supply of
organic CBD, as Khrysos has both cannabis cultivation property and
facilities to refine CBD oil.
With that backdrop, Youngevity recently launched HempFX to sell its products directly to
consumers. For the moment, the company is offering hemp oils. Its
product line may increase as additional research and development
brings more ideas to market.
A Coffee Door Opener
Youngevity is also ready to bring a CBD-infused coffee to market. Its recent acquisition
of Khrysos Global brought CBD-testing laboratories to the company,
looking to leave Youngevity in a position to take full advantage of
the new U.S. CBD laws. One of the biggest hurdles for manufacturers
of CBD products is making sure the products contain a repeatable
dose of CBD. Through careful testing, Youngevity has overcome this
obstacle in its coffee, which reliably delivers 10mg of CBD in
every cup.
The new coffee will be made by Youngevity's wholly owned
subsidiary CLR Roasters. According to the company, the new product
will be sold in four flavors and will be available to consumers
later this year.
CLR Roasters president Ernesto Aguila commented,
“We are extremely pleased with the taste of the product, and the
samples that we have provided to a host of retailers have led to
strong reviews as well. It is very exciting to bring a new product
to market that has so much interest within the coffee beverage
category. I have not seen a door opener like this since Javalution
Coffee Company created the first fortified coffees.”
Market Viability Looks Strong
CBD has essentially been illegal since modern medicine began.
Now that it is legal to produce and distribute CBD in the United
States, early movers in the space are setting themselves up for
potentially massive profits. Numerous companies are focusing on
developing better CBD-infused products, creating new forms of
consumer-focused CBD consumables and getting those products to
consumers as quickly and easily as possible.
CV Sciences Inc. (OTCQB: CVSI) is working to
commercialize CBD products for both consumers and the medical
community. Its pharmaceutical division is looking to create a
CBD-based medicine that can be approved by the U.S. Food and Drug
Administration. Now that CBD is 100 percent legal at a federal
level in the United States, the company should be able to make
progress on this project. Its consumer division is developing a
range of products that can be sold to health food stores or
directly to its customers. As CBD use has become more widespread,
there is a growing amount of feedback from users to support its
continued development.
Isodiol International Inc. (CSE: ISOL) (OTCQB:
ISOLF) has built a CBD-focused business with operations in
the United States, the United Kingdom, and other countries.
Kevin Swadish, the company's chief revenue officer,
commented, “The legalities of hemp-based CBD are becoming more
favorable, and consumer awareness of CBD is rapidly rising. As a
result, we believe the greatest growth opportunities in the
industry, and for Isodiol, lie in the consumer packaged goods
marketplace.” The company has built up an operation with more than
200 employees and consultants globally, which demonstrates the
interest CBD has generated in recent years.
GW Pharmaceuticals plc (NASDAQ: GWPH) (OTC:
GWPRF) developed the first marijuana-derived
pharmaceutical to be approved by the FDA. Epidiolex, which contains
CBD, was designed to treat Dravet syndrome and was the first drug
ever approved to treat this rare form of epilepsy in the U.S. Sales
of the drug began last November, and according to recent financial
results posted by the company, Epidiolex has garnered substantial
interest. Epidiolex sales totaled around $4.7 million in the last
quarter, with more than 4,500 new patient enrollment forms during
the first two months the drug was available. The positive results
from Epidiolex sales were well received, and investors bid the
company's shares higher after they were announced.
Getting CBD products into the hands of consumers is also a focus
for savvy companies looking to the future. Curaleaf
Holdings Inc. (OTCQX: CURLF) (CSE: CURA) recently announced a distribution deal with CVS Health Corp.
Under the new deal, the retail pharmacy and healthcare company will
begin selling products infused with the trendy, nonintoxicating
hemp component at more than 800 of its stores nationwide. CVS
confirmed that it has started selling CBD creams, sprays and
lotions in eight states, including California, Illinois, Colorado
and Alabama. The products will be sold in store aisles. “We’ve been
having dialogue with national retailers for many months now,” said
Curaleaf chief executive officer Joseph Lusardi. “We’ve got a
number of potentially exciting partnerships in the pipeline.”
Growing hemp and refining it into CBD could become profitable
for companies that can do it efficiently, especially if public
demand grows faster than production capacity. Youngevity may be
picking up on this emerging market dynamic and securing its
supplies of organic CBD while the industry is still in its
infancy.
For more information on Youngevity, visit Youngevity
International, Inc. (NASDAQ: YGYI)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services,
and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with
an extensive team of contributing journalists and writers, CNW is
uniquely positioned to best serve private and public companies that
desire to reach a wide audience of investors, consumers,
journalists and the general public. CNW has an ever-growing
distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information
in today’s market, CNW brings its clients unparalleled visibility,
recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and
or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Isodiol (CE) (USOTC:ISOLF)
Historical Stock Chart
From Nov 2024 to Dec 2024
Isodiol (CE) (USOTC:ISOLF)
Historical Stock Chart
From Dec 2023 to Dec 2024
